• Rachita Dhurat Lokmanya Tilak Municipal Medical College & Lokmanya Tilak Municipal General Hospital, Mumbai
  • KANWAR AJ Postgraduate Institute of Medical Education & Research, Chandigarh
  • VISHALAKSHI VISHWANATH Rajiv Gandhi Medical College & Chhatrapati Shivaji Maharaj Hospital, Mumbai
  • NITI KHUNGER Safdarjung Hospital, New Delhi
  • Sudhakar Grandhi Skin Care Clinic, Pune
  • Nimesh Mehta N M Skin & Cosmetology Clinic, Mumbai
  • Amit Bhargava Glenmark Pharmaceuticals Ltd., Mumbai
  • Amanjit Ahluwalia Glenmark Pharmaceuticals Ltd., Mumbai
  • Rujuta Vaidya Glenmark Pharmaceuticals Ltd., Mumbai


Psoriasis is a common, chronic, inflammatory, multisystem disease involving the skin and joints. It accounts for 2.3% of the total dermatology outpatients in India.  Corticosteroids have an important role in skin diseases because of their anti-inflammatory, immunosuppressive, and anti-proliferative effects on the keratinocytes.

Topical corticosteroids are commonly used in the management of psoriasis and other inflammatory skin disorders. Clobetasol 0.05% ointment and halobetasol 0.05% ointment are synthetic class I super-potent topical corticosteroids with anti-inflammatory, anti-pruritic and vasoconstrictive properties commonly prescribed for the treatment of psoriasis. The current study conducted in 202 patients from 6 centers showed a significant reduction in LPSI scores at end of treatment. The physician's global evaluation rating at end of treatment of almost total clearing of lesion (Grade 4) was reported in 19.2% and 32% patients, marked improvement (Grade 3) in 47.5% and 50.5%, moderate improvement (Grade 2) in 30.3% and 17.5% and mild improvement (Grade 1) in 3% and 0% for Clobetasol and Halobetasol groups respectively. The difference between the two groups for physicians' global evaluation was found to be statistically significant (p=0.019). 19.2% and 27.2% patients in Clobetasol and Halobetasol respectively, showed >75% improvement in photographic assessment (p=0.521).  There was a significant difference in the cosmetic acceptability (p=0.042) & in the ease of application (p=0.019) between the two groups.  No significant difference was found in serum cortisol levels, in both groups (p=0.074).

Therefore this study reaffirms that halobetasol has better efficacy and good tolerability profile compared to clobetasol.


1. Kaur I, Handa S, Kumar B. Natural history of psoriasis: a study from the Indian subcontinent. J Dermatol 1997;24:230-4.
2. van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J ClinDermatol 2001;2:159-65.
3. Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. ClinDermatol 2008;26:448-59.
4. Goldberg B, Hartdegen R, Presbury D, Smith EH, Yawalkar S. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am AcadDermatol. 1991 Dec;25(6 Pt 2):1145-8.
5. Abidi A, Ahmad F, Singh SK. A comparative clinical evaluation of once daily versus alternate day application of topical clobetasol propionate cream in psoriasis. J ClinDiagn Res. 2013 Jan;7(1):100-5.
6. Rivera AM, Hsu S. Topical halobetasol propionate in the treatment of plaque psoriasis: a review.Am J ClinDermatol. 2005;6(5):311-6.
7. Pearce DJ, Spencer L, Hu J, Balkrishnan R, Fleischer AB Jr, Feldman SR. Class I topical corticosteroid use by psoriasis patients in an academic practice. J Dermatolog Treat. 2004 Jul;15(4):235-8.
8. Mensing H, Korsukewitz G, Yawalkar S. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. J Am AcadDermatol. 1991 Dec;25(6 Pt 2):1149-52.
450 Views | 634 Downloads
How to Cite
Dhurat, R., K. AJ, V. VISHWANATH, N. KHUNGER, S. Grandhi, N. Mehta, A. Bhargava, A. Ahluwalia, and R. Vaidya. “EVALUATION OF THE EFFICACY AND SAFETY OF 0.05% HALOBETASOL PROPIONATE OINTMENT AND 0.05% CLOBETASOL PROPIONATE OINTMENT IN CHRONIC, LOCALIZED PLAQUE PSORIASIS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 9, no. 1, Jan. 2016, pp. 288-91, https://innovareacademics.in/journals/index.php/ajpcr/article/view/9696.
Original Article(s)